EpimAb Biotherapeutics Announces Upcoming Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) SHANGHAI, Oct. 11, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased to...

EpimAb Biotherapeutics and Vignette Bio Announce Strategic Collaboration to Develop EMB-06, a BCMA×CD3 Bispecific Antibody SHANGHAI and SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, Inc. (“EpimAb” or “EpimAb Biotherapeutics”) a clinical stage biopharmaceutical company specializing in the...